Recent clinical trials with monoclonal antibodies that block CGRP or its receptor [43, 44], underline the hypothesis that the pain produced by CGRP during migraine attacks originates at a peripheral site, outside the blood brain barrier. Here, CALCA is linked to migraine disorder.